Find a Doctor or Practice Location

Are you a referring physician?
I am searching for a
Reset Form
Richard L. Dunbar, MD

Richard L. Dunbar, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Dunbar is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties


  • Medical Genetics

Programs & Centers:

Board Certification:

  • Internal Medicine, 2015

Clinical Expertise:

  • Cardiac Risk Reduction
  • Cardiology Risk Intervention
  • Cholesterol and Lipid Disorders
  • High Cholesterol (Hypercholesterolemia)
  • Hyperlipidemia (Hyperlipoproteinemia)
  • Lipid Disorders
  • Lipid Disorders Management
  • Preventive Heart Care

Description of Clinical Expertise

Dr. Dunbar specializes in the treatment of cholesterol disorders, and practices in the Preventive Cardiology Clinic at the Pereleman Center for Advanced Medicine

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Medical College of Virginia
Residency: Medical College of Virginia Hospitals


American College of Physicians, National American Heart Association, National American Society for Biochemistry and Molecular Biology (Member), National Christian Medical and Dental Associations, National National Lipid Association, National Northeast Lipid Association, National Philadelphia Lipid and Atherosclerosis Club, Local South Jersey Christian Medical and Dental Association, Local

Hospital Affiliation

Dr. Dunbar is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Dr. Dunbar is interested in atherogenic dyslipidemia and its treatment, and has particular expertise in the mechanism of action and adverse effects of triglyceride-lowering drugs. He has worked with a variety of several novel triglyceride-lowering compounds, including niacin and novel niacin mimetics, fibrates and novel fibrates, novel fish oils, and a host of other emerging drugs: DGAT-1 inhibitor, MTP inhibitor, AngPTL3 inhibitor, ApoC3 inhibitor, a glitazar, and perhaps most uniquely, lipoprotein lipase gene replacement therapy. He also employs a variety of provoked outcomes in his research, such as oral fat tolerance testing with/without radiolabeled fat to trace chylomicrons, stable isotope lipoprotein kinetics, euglycemic-hyperinsulinemic clamp, FSIVGTT, indocyanine green to test hepatic function, other nutrient challenges, and a variety of modalities to measure niacin-associated skin toxicity. A common theme of these is the concept that perturbing a system reveals more as an outcome than the steady state. His research focuses on translating pre-clinical findings into humans, and indeed works exclusively on patient-oriented, clinical research.

Selected Publications:

Tuteja S, Wang L, Dunbar RL, Chen J, DerOhannessian S, Marcovina SM, Elam M, MD, Lader E, Rader DJ: Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2 (HCA2), and response to niacin therapy Pharmacogenetics and Genomics 27 (8): 285-293,2017.

Dewey FE*, Gusarova V*, Dunbar RL*, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV , Bruse S, Dansky HM , Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH , Lee I-T, Liang K-W, Guo X, Rotter JI, Chen Y-D I on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM: Genetic and Pharmacologic Inactivation of ANGPTL3 and Atherosclerotic Cardiovascular Disease N Engl J Med 377 (3): 211-221,2017.

Millar JS, Lassman ME, Thomas T, Ramakrishnan R, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Wagner JA, Holleran S, Obunike J, Liu Y, Aoujil S, Standiford T, Gutstein DE, Ginsberg HN, Rader DJ, Reyes-Soffer G: Effects of CETP Inhibition with Anacetrapib on Metabolism of VLDL TG and Plasma Apolipoproteins C-II, C-III, and E J Lipid Res 58 (6): 1214-1220,2017.

Ueda M*, Dunbar RL*, Wolska A, Sikora TU, del Rosario Escobar M, Seliktar N, deGoma E, DerOhannessian S, Morrell L, McIntyre AD, Burke F, Sviridov D, Amar M, Shamburek RD, Freeman L, Hegele RA, Remaley AT, Rader DJ: A Novel APOC2 Missense Mutation Causing Apolipoprotein C-II Deficiency With Severe Triglyceridemia and Pancreatitis. J Clin Endocrinol Metab 102 (5): 1454-1457,2017.

Ueda M, Burke FM, Walters L, Lalic D, Sikora, Greene H, DerOhannessian S, McIntyre A, deGoma E, Hegele RA, Rader DJ, Dunbar RL: Familial Chylomicron Syndrome: Importance of Discerning the Rare Among the Common J Clin Lip 11 (3): 2017.

Dunbar, RL: Signs, Symptoms and Awareness of FCS with Dr Richard Dunbar Rare Disease Report, accessioned from : 2017.

Goldberg AC, Dunbar RL, Hemphill L, Babirak SP, Wilson G, Wooten M, Moriarty PM: Retrospective Review of the Effect of Alirocumab on Apheresis J Clin Lip 11 (3): 2017.

Cuchel M, Raper AC, Pryma DA, Freifelder RH, Poria R, Cromley D, Li X, Dunbar RL, French B, Qu L, Farver W, Su C-C, Lund-Katz S, Baer A, Ruotolo G, Akerblad P, Ryan CS, Xiao L, Kirchgessner TG, Millar JS, Billheimer JT, Rader DJ: A Novel Approach to Measuring Macrophage-specific Reverse Cholesterol Transport in Vivo in Humans. J Lipid Res 58 (4): 752-762,2017.

Dunbar RL*, Goel H*, Tuteja S, Song W-L, Nathanson G, Babar Z, Lalic D, Gelfand JM, Rader DJ, Grove GL: Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. J Lipid Res 58 (4): 783-797,2017.

Dunbar RL, Movva R, Bloedon LT, Duffy D, Norris RB, Navab M, Fogelman AM, Rader DJ: Oral Apolipoprotein A-I Mimetic D-4F Lowers HDL-Inflammatory Index in High-Risk Patients: A First-in-Human Multiple-Dose, Randomized Controlled Trial Clin Trans Science 10 : 2017.

View all publications

Academic Contact Info

Academic Office:
Perelman School of Medicine at the University of Pennsylvania
3600 Spruce Street, 9-010 Maloney Building

Preventive Cardiovascular Medicine Clinic
3400 Civic Center Blvd, 2nd Floor, East Pavilion

Philadelphia, PA 19104
Phone: Clinic (215) 615-8659
Patient appointments: 800-789-7366 (PENN)

Related Links